Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 04 tags : Fda save search
GE Healthcare Receives FDA Approval of First-Ever Software to Help Automate Anesthesia Delivery and Reduce Greenhouse Gas Emissions During Surgery
Published: 2022-04-04 (Crawled : 20:00) - biospace.com/
GE | News | $162.62 8.28% 0.22% 19M
|
Electronic Technology
|
| O: -0.34%
H: 0.15%
C: -0.17%
fda approval software
Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
Published: 2022-04-04 (Crawled : 13:20) - biospace.com/
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -0.6%
H: 0.94%
C: 0.86%
fda system heart approval
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
Published: 2022-04-04 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 24.66%
H: 3.57%
C: -16.48%
fda granted therapy edsivo celiprolol grant designation
Apyx Medical Corporation Announces FDA 510(k) Submission with Clinical Study Support for the Use of the Renuvion® APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin
Published: 2022-04-04 (Crawled : 12:20) - biospace.com/
APYX | $1.33 5.56% 5.26% 55K
|
Health Technology
|
| O: -0.59%
H: 1.19%
C: -2.24%
renuvion fda aesthetic skin corporation submission
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
Published: 2022-04-04 (Crawled : 12:20) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 0.0%
H: 0.0%
C: 0.0%
fda therapeutics phase 1
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
Published: 2022-04-04 (Crawled : 07:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.01%
H: 1.97%
C: 1.67%
covid-19 treatment fda review
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Published: 2022-04-04 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.74%
H: 0.6%
C: -0.23%
dupixent fda review order
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Published: 2022-04-04 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.74%
H: 0.6%
C: -0.23%
dupixent fda review order
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.